Many studies show that systemic inflammation marker levels should be taken into account as a key factor causing extrapulmonary complications and progression of the disease. However, assessment of systemic inflammation severity is not always used in routine medical practice to determine the severity of COPD.
Aim: Determine the severity of systemic inflammation by measuring serum SAA and CRP levels during the stable phase of the disease in COPD patients who received different treatments.
Materials and Methods: We have examined 37 COPD patients. Patients examination included general clinical methods, questionnaires for detecting of severity of symptoms, detecting severity of systemic inflammation by measuring serum SAA and CRP levels. Patients were divided into two subgroups depending on the treatment which they received. Patients of both subgroups were screened twice – at baseline (visit 1) and three months after assignment of adequate standard therapy (visit 2).
Results: If treated inadequately, COPD patients in the stable phase, regardless of severity of their condition, suffer from more intense symptoms, have more relapses over the previous year, and their systemic inflammation levels are higher than in patients who receive long-term therapy adequate to their COPD. Proper three-month COPD treatment helps improve the symptoms to the levels found in patients who receive longer adequate therapy. As soon as three months after initiation, correctly assigned COPD treatment helps reduce systemic inflammation significantly by CRP levels and slightly by SAA levels.